Introduction
Despite the development of virologically effective combination antiretroviral therapy (cART), cognitive impairment remains frequently reported in HIV-positive individuals, with several different diagnostic classification systems currently in use [1] . The implicit assumption is that those with cognitive impairment are more likely to have a higher frequency of mental and physical complaints as part of a general syndrome of ill health. While severe cognitive impairment has previously been associated with impairment of objective measures of everyday functioning, such reports were derived in patient populations with lower CD4 lymphocyte cell counts than are typically seen in the current era, and in whom cART regimens would now be considered suboptimal [2, 3] . Additionally, while associations with cognitive impairment and patient-related outcomes may be statistically significant, the clinical significance of the associations seen is unclear. We aimed to test the hypothesis that cognitive impairment would be associated with other measures of mental and physical dysfunction in a contemporary cohort of HIV-positive individuals.
Methods

Participants
Participants were prospectively enrolled into the Pharmacokinetic and Clinical Observations in People Over Fifty (POPPY) study (ClinicalTrials.gov Identifier: NCT01737047). This multicentre cohort study aims to investigate the effects of ageing and comorbidities on HIV-positive individuals in the UK and Ireland. Inclusion criteria were documented presence or absence of HIV infection, self-defined white or black African ethnicity, age over 50 years at study entry and the ability to comprehend the study patient information leaflet. Additional inclusion criteria for the HIV-positive participants were probable route of HIV acquisition via sexual exposure (either by male-to-male exposure if white or by heterosexual exposure if white or black African). Considerable care was taken to recruit appropriate HIV-negative controls from sexual health clinics and using targeted community advertising and to frequency match the controls to the HIV-positive participants by gender, ethnicity, sexual orientation and location (in or outside London).
The study was approved by the UK National Research Ethics Service (NRES; Fulham, London, UK; reference number 12/LO/1409). All participants provided written informed consent.
Cognitive function testing
All participants underwent cognitive function testing using a computerized battery (Cogstate Ltd, Melbourne, Australia) covering six cognitive domains including visual learning, psychomotor function, visual attention, executive function, verbal learning and working memory (Supplementary Table S1 ). This has been shown to be a sensitive diagnostic tool for the assessment of HIV-associated cognitive impairment and allows standardized assessment across sites to be completed in a reasonable amount of time [4] .
Raw test scores were log-transformed or arcsine roottransformed where necessary (as per CogState analysis guidelines) and converted into demographically adjusted T-scores (mean 50; standard deviation 10) using the HIVnegative control group as the reference population accounting for age, level of education, gender and ethnicity as appropriate. This method was used as the CogState norms do not account for the range of age of participants in our study. Within each cognitive domain, individual Tscores were averaged to calculate the domain T-score, and these domain T-scores were averaged across domains to calculate the global T-score. For all T-scores, higher scores indicate better cognitive function.
Cognitive impairment was defined using published methods for HIV-associated neurocognitive disorder, commonly known as the "Frascati" criteria (applied to domain T-scores to minimize multiple testing) [5] , the global deficit score (GDS) [6] and multivariate normative comparison (MNC) [7] . We subdivided those with Frascati-defined impairment, using Lawton Instrumental Activities of Daily Living (IADL) [3] , for descriptive purposes only to avoid circularity in assessing the relationship between objective cognitive impairment and subjective symptomology. We also tested a more stringent, combined definition of cognitive impairment whereby participants had to meet the Frascati, GDS and MNC criteria to be defined as impaired as well as using a global T-score cut-off of < 45. This is equivalent to a change in z-score of 0.5 which is thought to represent a clinically significant difference in cognitive function and has been used as a primary outcome in clinical trials assessing interventions for the management of cognitive impairment in HIV disease [8] .
Patient-reported outcome measures (PROMs)
All participants answered the previously recommended cognitive complaints screening questions [9] : "Do you experience frequent memory loss?"; "Do you feel that you are slower when reasoning, planning activities, or solving problems?" and "Do you have difficulties paying attention?" Participants also completed validated questionnaires detailing: physical and mental health with the Short Form Health Survey (SF-36) [10] ; activities of daily living with the IADL [11] and depression with the Patient Depression Questionnaire (PHQ-9) [12] and the Centres for Epidemiologic Studies Depression scale (CES-D) [13] . Additionally, falls and sexual desire were assessed by asking "Over the past 28 days have you had any falls?" and "How often have you worried about minimal sexual desire during the last 4 weeks?" respectively. Outcomes were then dichotomized for further analysis (see supplementary data for details).
Statistical analysis
Demographic differences and comparisons of the prevalence of cognitive impairment between groups were assessed using the v 2 test and Wilcoxon rank-sum tests as appropriate. In the HIV-positive group, the classification performances of the different definitions of cognitive impairment with dichotomized questionnaire results were assessed using the concordance (or "c") statistic (equivalent to the area under the receiver operating characteristic curve). This gives an indication of the ability of the different definitions of cognitive impairment to discriminate between those with and without symptoms based on the questionnaire data. Concordance is typically considered reasonable when the c-statistic is > 0.7 and strong when it is > 0.8 [14] . In addition, sensitivity and specificity were calculated. Optimal global T-score cut-offs were calculated for each PROM by maximizing the c-statistic. Differences in physical and mental health between those with and without cognitive impairment were calculated using the Wilcoxon rank-sum tests. All analyses were performed using SAS v9.4 (SAS Institute Inc., Cary, NC, USA) and R v3.2.1 (R Foundation for Statistical Computing, Vienna, Austria). Only P-values (two-sided) < 0.05 were considered statistically significant. 
Cognitive function
HIV-positive participants exhibited higher rates of cognitive impairment compared with the HIV-negative control group (Table 1) . In general, cognitive impairment was mild, with only eight (2.8%) and six (2.1%) HIV-positive participants fulfilling the Frascati definitions of mild neurocognitive disorder and HIV-associated dementia, respectively. Cognitive impairment was not associated with recreational drug use in the last 6 months (P > 0.2 for cognitive impairment defined with Frascati, GDS or MNC) or duration of known HIV infection (P > 0.4). Using a global T-score cut-off of 45 to define cognitive impairment, the prevalence was 31.0% vs. 16.5% [odds ratio (OR) 2.28; 95% confidence interval (CI) 1.29-4.24; P < 0.01] for the HIV-positive vs. HIV-negative groups, respectively.
Patient-reported outcome measures (PROMs)
Of the HIV-positive participants with complete data, 79 (28.6%) reported frequent memory loss, 105 (38.2%) reasoning difficulties and 79 (28.9%) attention problems, 40 (14.3%) were not fully independent, 76 (28.9%) and 102 (39.1%) were depressed by PHQ-9 and CES-D scoring, respectively, 50 (17.9%) reported falls in the last 28 days, and 125 (45.1%) reported minimal sexual desire over the preceding 4 weeks. In general, the associations between cognitive impairment and PROMs were weak regardless of the method of identification of cognitive impairment used (Table 2) : mean c-statistics were 0.543 (GDS), 0.530 (MNC) and 0.519 (Frascati). Sensitivity analyses, excluding those with nervous system disorders, did not significantly GDS, global deficit score; MNC, multivariate normative comparison; Sens., sensitivity; Spec., specificity. *Cut-off that maximizes the c-statistic (i.e. the same weight to sensitivity and specificity).
change the associations. Using an alternative definition of cognitive impairment, based on a global T-score cutoff of < 45, associations with PROMS were not dramatically improved (mean c-statistic 0.560). Even using the combined measure of cognitive impairment (14.1% of HIV-positive and 6.2% of HIV-negative individuals), the associations were weak (mean c-statistic 0.534). Concordance was optimized (mean c-statistic of 0.582) by varying the global T-score threshold by which cognitive impairment was defined (range 41.3-47.6) to maximize both sensitivity and specificity ( Table 2 ). The strongest associations between cognitive impairment and symptoms were consistently seen with memory loss and in general the weakest were with sexual desire. Summary health scores (SF-36) were lower in those with vs. without cognitive impairment, for both mental and physical health (Supplementary Figure S1 ) but only significantly so for cognitive impairment identified with MNC (mental health : 61.4 vs. 75.8, P = 0.03; physical health: 60.9 vs. 75.0, P = 0.03 for those with vs. without impairment respectively).
Discussion
HIV-positive individuals exhibited poorer cognitive function when compared with an appropriate HIV-negative control group. As has been shown previously, the prevalence of cognitive impairment is sensitive to the method used [1] . This presents a problem when trying to assess associations with other outcomes, which is why we chose to study three commonly used definitions of cognitive impairment, their combination and the global T-score with varying cut-offs.
Regardless of the definition used, cognitive impairment correlated poorly with symptomatology. There are several possible explanations for our observations. Firstly, a lack of a "gold-standard" method of diagnosing cognitive impairment may have limited our ability to make such observations. To mitigate against this, we utilized several methods to define cognitive impairment in addition to trying different global T-score thresholds. Secondly, over-reporting of symptoms, whereby patients both with and without cognitive impairment report high rates of symptomatology, makes finding associations challenging. Thirdly, the subjectivity of some questions regarding mental state (e.g. memory) makes it difficult to establish a clear relationship between subjective experience and objective measures of cognitive function. Similar reasons may explain the weak associations between cognitive impairment and other PROMs. Our findings are in contrast to those of previous studies which reported poorer functional outcomes [2, 3] , which may be explained by differences in populations. Previously published studies tended to have low levels of suppressive cART use and more severe cognitive impairment. Because of the higher frequency of prior AIDSrelated events, participants were more likely to have accumulated disability. Therefore, it is likely that an increased severity of both cognitive impairment and symptomatology resulted in a stronger association between the two. In contrast, our study population was comparatively well and the vast majority of cognitive impairment was mild, with only 2% of the total HIVpositive population meeting the criteria of HIV-associated dementia. However, even using a stringent, combined definition of cognitive impairment, which only captures the most impaired, the associations with PROMS remained weak. This highlights the potential dichotomy between cognitive impairment and other PROMs. A longitudinal study is needed to assess prospectively the clinical impact of mild cognitive impairment.
Limitations
Although great effort was made to recruit a comparable control population, differences between the groups unrelated to HIV infection may exist. Therefore, not all the differences in cognitive impairment we report here may be secondary to HIV disease. To maximize recruitment and the generalizability of our findings, exclusion criteria were kept to a minimum. Cognitive impairment could therefore have been caused by degenerative neurological diseases other than HIV disease. However, rates of neurological diagnoses did not differ significantly between the groups, and therefore rates of cognitive impairment should not be biased towards one group.
Given that our study used a "real-world" sample and subjects were recruited prior to the publication of the International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) Strategic Timing of Antiretroviral Therapy (START) study, not every HIV-positive individual was receiving suppressive antiretroviral therapy [15] . cART prescribing was in line with national guidelines at the time of enrolment. Those not receiving cART in our study had a median CD4 count of 664 cells/lL, which makes it unlikely that lack of suppression of HIV replication in a minority is skewing our findings. Additionally, given the poor concordance of cognitive impairment with other PROMs, it seems unlikely that excluding a small percentage of our sample would dramatically change our results.
